/NOT FOR THE DISTRIBUTION OF ARTICLES OR SOFTWARE UNITED STATES/
VANCOUVER, BC, January 20, 2023 /CNW/ – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA), is pleased to announce the soft launch of the “NARA DNA Reports” feature available through its website. nara.care. The company has launched its first report of the series, the NARA MIND report as its first product that can be purchased. $189.00 USD. In addition, the Company announced today that, continuing its news release on December 23, 2022has closed the final tranche (“Final Tranche”) of its private offering (“Offer”) of units (each a “Unit”) at a price of $0.15 per Unit, for all earnings under Contribution of $512,250. Finally, the Company also announced that it has retained Pulse Investor Relations Services Inc. (“PulseIR”) to provide digital marketing services for business relationships.
Nara DNA Reports
The NARA MIND report will provide users with unique mental health information covering their genetic makeup, micronutrient sensitivity, nutritional profile and metabolic profile.
Nara creates a personalized DNA Report by searching for a user’s unique DNA that is specifically associated with important genes related to mental health. With the personal information that users get through analytics and reports, the Company believes that users can take steps to improve their health.
“I am very excited to announce this new feature as part of the PanGenomic solution for personalized care,” he said. Maryam MarissenCEO and President of PanGenomic Health Inc. “NARA DNA Reports will be expanded to include additional DNA reports in the coming months.”
Overcommitment and Performance of Prior Commitments
The company also announced that, continuing its news release on December 23, 2022The Company closed the final tranche (“Final Tranche”) of its private offering (“Offering”) of units (each a “Unit”) at a price of $0.15 per Unit, for all earnings under Contribution of $512,250.
Each Share under the Offering consists of one (1) share of Share A Common (each, a “Share”) of the Company and one (1) share of Share A Common to purchase (each, a “Description”). Each license can be used for one additional session at the exercise price of $0.30 for a period of 24 months from the date of issue. If the closing price of the Shares on the Canadian Securities Exchange is greater than or equal to $0.60 for 10 consecutive trading days, the Company reserves the right to accelerate the expiration date of the Certificates. Holders of the Certificates will be notified of the Company’s application of the Acceleration through a press release, after which they will have 30 days to exercise the Certificates.
The Final Tranche under the Offering consisted of 2,081,667 Units for a total amount of $312,500. Combined with the first phase, Contributions have resulted in total revenue $512,250 from issuing 3,415,000 Units. In connection with the closing of the Final Tranche, the Company paid the registered broker a fee of $750. The Company will use all proceeds from the Offering to continue to develop and market its Nara, Mindleap and PlantGx products and for operational purposes.
All securities related to the Final Tranche are subject to a fixed term under statutory regulations of four months and one day from the date of issue.
In addition to closing the Offer, the Company is also pleased to report that approximately 95% of the documents already issued by the company have a trial value. $0.10 for each Part used before the expiration date January 132023. The company raised approx $409,000 in the use of these symbols.
This article does not constitute an offer to sell or a solicitation to buy securities of the Company United States. The securities offered by the company have not been and will not be registered under the United States Securities Act of 1933, as amended (the “US Securities Act”), or any other federal securities laws and may not be offered or sold internally. United States or to US Persons unless they are registered under the US Securities Act and applicable government securities laws, or are submitted to registered securities.
PulseIR compatibility
The company also announced that it has retained Pulse Investor Services Inc. (“PulseIR”) to provide digital marketing services for business relationships. Under the terms of the agreement, PulseIR will provide its communication wallets at a reasonable cost to the Company of $120,000 for the first contract period of twelve months from January 16, 2023. PulseIR participated in the offering by subscription of 840,000 Units at a total value of $126,000.
PulseIR is a digital marketing and consulting firm Vancouver, BC. After the company entered into this new partnership with PulseIR, it terminated a capital markets advisory and digital marketing services agreement with Bello Capital Partners, which was previously announced on. January 3, 2023. No termination fee was charged by the Company.
About PanGenomic Health
PanGenomic Health is a precision healthcare company that has developed a self-care platform to provide personalized, evidence-based information on natural medicine. The company’s first goal is to help the mentally ill. He was registered as a British Columbia a profitable company, the mission of PanGenomic Health is to promote and improve the health and well-being of people and people by providing a technology platform that identifies ways to produce seeds compatible with the health of each person.
This article also includes certain statements that may be considered “forward-looking statements”, including statements respecting services to be provided by PanGenomic and services to be provided to PanGenomic. The use of any words such as “expect”, “continue”, “estimate”, “anticipate”, “may”, “would”, “would”, “work”, “should”, “believe” and similar words wishes to recognize forward-looking statements. Although PanGenomic believes that the expectations and assumptions on which forward-looking statements are based are reasonable, undue reliance should not be placed on forward-looking statements because PanGenomic can give no assurance that they will prove to be accurate. Because forward-looking statements relate to future events and conditions, they inherently involve risks and uncertainties. These words only speak from the date of the News Release. In particular, there can be no assurance that the Company will be able to sell any other securities under the Offering. Actual results may differ from those currently anticipated due to a number of factors and risks including various risks described in PanGenomic’s disclosure documents which can be found under PanGenomic’s profile at www.sedar.com.
The Canadian Securities Exchange has not endorsed or disapproved of the content of this article and accepts no responsibility for the completeness or accuracy of this article.
Company opinion PanGenomic Health Inc.
Check out the source to download the soundtrack: http://www.newswire.ca/en/releases/archive/January2023/20/c4627.html
